ArticleInfectious diseases and therapy2025

Cost-Effectiveness and Public Health Impact of Universal Prophylaxis with Nirsevimab Against Respiratory Syncytial Virus (RSV) Infections in all Infants in Japan.

Shinichi Noto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.